Skip to Content
Merck
CN
  • ¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

Anticancer research (2015-05-13)
Vincent Camus, Agathe Edet-Sanson, Michael Bubenheim, Anne Hitzel, Stéphanie Becker, Marion David, Aspasia Stamatoullas, Pascal Lenain, Fabrice Jardin, Nathalie Contentin, Marie Laure Fontoura, Nathalie Cardinael, Sandrine Vaudaux, Sydney Dubois, Hervé Tilly, Pierre Vera, Stéphane Leprêtre
ABSTRACT

The aim of the present study was to assess the prevalence of hyper-metabolic infection sites revealed by fluorine-18 ((18)F) fluorodeoxyglucose (FDG) positron-emission tomography (PET) combined with computed tomography (CT) in patients with febrile neutropenia (FN). Forty-eight consecutive patients with haematological malignancies and persistent FN (temperature ≥ 38°C and neutrophil count <500 cells/μl for more than two days) as a consequence of intensive chemotherapy were prospectively included. Pathological FDG uptakes identified 31 foci of infections located in the lungs (n=15, 48.4 %), colon (n=4, 12.9%), pancreas (n=2, 6.5%), skin (n=3, 9.7%), ear-nose-throat area (n=5, 16.1%), central venous catheter tract (n=1, 3.2%) and gallbladder (n=1, 3.2%). These pathological FDG uptakes were observed in half of the 48 patients (n=24). Among the 38 patients with a clinical diagnosis of infection, 23 showed a pathological FDG uptake, resulting in a FDG-PET/CT sensitivity of 61% (95% CI, 43-76%). Our study confirmed the ability of FDG-PET/CT to diagnose infections in patients with persistent FN.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tantalum(V) ethoxide, 99.98% trace metals basis
Tantalum(V) ethoxide, packaged for use in deposition systems
Sigma-Aldrich
Fluorescein di(β-D-galactopyranoside)